Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases
Issued Date
2024-02-08
Resource Type
eISSN
15732630
Scopus ID
2-s2.0-85184706204
Pubmed ID
38329659
Journal Title
International ophthalmology
Volume
44
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
International ophthalmology Vol.44 No.1 (2024) , 33
Suggested Citation
Sukon N., Choopong P., Tungsattayathitthan U., Tesavibul N., Sanpan W., Boonsopon S. Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases. International ophthalmology Vol.44 No.1 (2024) , 33. doi:10.1007/s10792-024-02980-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97268
Title
Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
PURPOSE: To investigate for association between skin autofluorescence (SAF) advanced glycation end products (AGEs) and uveitis/scleritis activity in systemic inflammatory disease-related active non-infectious uveitis/scleritis patients. METHODS: This cross-sectional study was conducted at Siriraj Hospital during October 2019 to March 2020. AGEs were measured by SAF method in systemic immune-related disease patients with active uveitis/scleritis, and those results were compared with those of healthy age-matched controls. RESULTS: Thirty-one active non-infectious uveitis/scleritis patients and 31 age-matched controls were enrolled. The mean age of patients was 40.0 ± 12.8 years, and most were female (55.0%). The most common associated systemic immune-related disease was Vogt-Koyanagi-Harada disease (n = 14). Mean SAF AGE level in the study group compared to the control group was 2.38 ± 0.66 arbitrary units (AU) versus 2.58 ± 0.56 AU, respectively (p = 0.20). Multivariate analysis showed decreased SAF AGE level to be significantly associated with active ocular inflammation, (odds ratio: 0.01, 95% confidence interval: 0.00004-0.81; p = 0.04). CONCLUSIONS: SAF AGE level was not so far found to be a reliable biomarker for indicating uveitis/scleritis activity in systemic immune-related disease patients with active ocular inflammation. CLINICAL TRIAL REGISTRATION: Thai Clinical Trials Registry, https://www.thaiclinicaltrials.org/ . (Reg. No. TCTR20200114004, registered date 01/01/2020, beginning date of the trial 10/01/2019).